As we turn the page to 2021, we expect at least two major cases to be resolved that could have long-lasting effects on where and how Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) cases are litigated. Specifically, the future of skinny labels is in doubt, and available venue Read More>>
Categories Courts, District Courts, Federal Circuit, Guest Contributors, IP News, IPWatchdog Articles, Litigation, Patents, Biologics Price Competition and Innovation Act, biosimilars, CAFC, generic drugs, Guest Contributor, Hatch-Waxman Act, intellectual property, patent, patent infringement, Patent Litigation, patents, skinny labels
